F573 for Injection Phase Ia Clinical Trial
Latest Information Update: 09 Nov 2022
At a glance
- Drugs F 573 (Primary)
- Indications Liver failure
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Beijing Continent Pharmaceutical
- 07 Nov 2022 Status changed from recruiting to completed.
- 28 Mar 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 28 Mar 2022 Planned primary completion date changed from 31 Dec 2021 to 31 Aug 2022.